Overexpression of miR-202 resensitizes imatinib resistant chronic myeloid leukemia cells through targetting Hexokinase 2

Chronic myeloid leukemia (CML) is a myeloproliferative disease which uniquely expresses a constitutively active tyrosine kinase, BCR/ABL. As a specific inhibitor of the BCR-ABL tyrosine kinase, imatinib becomes the first choice for the treatment of CML due to its high efficacy and low toxicity. Howe...

Descripción completa

Detalles Bibliográficos
Autores principales: Deng, Yingjun, Li, Xin, Feng, Jinxin, Zhang, Xiangliang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Portland Press Ltd. 2018
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5938424/
https://www.ncbi.nlm.nih.gov/pubmed/29559564
http://dx.doi.org/10.1042/BSR20171383

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5938424/
https://www.ncbi.nlm.nih.gov/pubmed/29559564
http://dx.doi.org/10.1042/BSR20171383

Ejemplares similares